{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/angiotensin-converting-enzyme-inhibitors/","result":{"pageContext":{"chapter":{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors","depth":2,"htmlHeader":"<!-- begin field e76ffcd2-a79d-4720-be4e-a71600d6b3cc --><h2>Angiotensin-converting enzyme inhibitors</h2><!-- end field e76ffcd2-a79d-4720-be4e-a71600d6b3cc -->","summary":"","htmlStringContent":"<!-- begin item 43da9959-f675-432f-b479-a71600d6b3ec --><!-- end item 43da9959-f675-432f-b479-a71600d6b3ec -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a763a80d-993e-596c-be77-bd079ce917d5","slug":"choice-of-ace-inhibitor","fullItemName":"Choice of ACE inhibitor","depth":3,"htmlHeader":"<!-- begin field ea2839f5-2e17-40c9-81bf-a71600d75aad --><h3>Which angiotensin-converting enzyme inhibitor is recommended?</h3><!-- end field ea2839f5-2e17-40c9-81bf-a71600d75aad -->","summary":"","htmlStringContent":"<!-- begin item aa29a715-d7de-4a40-9306-a71600d75b05 --><!-- begin field 95ee27cc-0475-4d03-af89-a71600d75aad --><ul><li>The choice of angiotensin-converting enzyme inhibitor usually depends on the person's co-morbidities, local recommendations, and cost.<ul><li>For people with heart failure and hypertension, enalapril, lisinopril, ramipril, and trandolapril may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li>For people who have diabetes and hypertension, enalapril, lisinopril, perindopril, ramipril, or trandolapril may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li></ul></li><li>For people who have had a previous myocardial infarction (without heart failure), lisinopril, perindopril, or ramipril may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.</li></ul></li></ul></li><li>Where possible, prescribe a drug that is taken only once a day and prescribe non-proprietary drugs where these are appropriate and minimise cost.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 95ee27cc-0475-4d03-af89-a71600d75aad --><!-- end item aa29a715-d7de-4a40-9306-a71600d75b05 -->","subChapters":[]},{"id":"101a994c-d6f3-5009-8811-2540daecd2fc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9f33624e-0649-4a9d-8d77-a71600d799a0 --><h3>Contraindications and cautions</h3><!-- end field 9f33624e-0649-4a9d-8d77-a71600d799a0 -->","summary":"","htmlStringContent":"<!-- begin item 0ab6733d-0dea-4f65-8075-a71600d799fb --><!-- begin field 5e7ef3c3-f711-42f1-8852-a71600d799a0 --><ul><li><strong>Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in:</strong><ul><li>People with history of angioedema associated with previous exposure to an ACE inhibitor.</li><li>People with hereditary or recurrent angioedema.</li><li>People with diabetes mellitus, or with an estimated glomerular filtration rate (eGFR) less than 60 mL/minute/1.73 m<sup>2</sup>, who are also taking aliskiren.</li><li>Pregnant women and those planning a pregnancy — due to risks to the fetus. Treatment with an ACE inhibitor should ideally be stopped as soon as pregnancy is detected and, if appropriate, alternative treatment should be started.<ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/pre-conception-advice-management/\">Pre-conception - advice and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</li></ul></li><li>Breastfeeding women — ACE inhibitors are not recommended as there is limited information on their safety.</li></ul></li><li><strong>ACE inhibitors should be used with caution in people:</strong><ul><li>Of black African or Caribbean origin, or with primary aldosteronism — may respond less well to ACE inhibitors.</li><li>With renal impairment — hyperkalaemia and other adverse effects are more common, and the dose may need to be reduced. </li><li>Taking diuretics.</li><li>With peripheral vascular disease or generalised atherosclerosis — due to risk of clinically silent renovascular disease.</li><li>With hypertrophic cardiomyopathy.</li><li>With severe or symptomatic aortic stenosis — due to risk of hypotension.</li><li>With collagen vascular disease — possible increased risk of agranulocytosis — blood counts recommended.</li></ul></li><li><strong>Note: </strong>people taking high doses of diuretics, on a low sodium diet, on dialysis, who are dehydrated, or who have heart failure, may be more likely to experience first-dose hypotension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 5e7ef3c3-f711-42f1-8852-a71600d799a0 --><!-- end item 0ab6733d-0dea-4f65-8075-a71600d799fb -->","subChapters":[]},{"id":"3415ea5b-bb2e-55e7-8973-d4fa3d083b06","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9b06faa5-99e9-449f-8d68-a71600da4f31 --><h3>Adverse effects</h3><!-- end field 9b06faa5-99e9-449f-8d68-a71600da4f31 -->","summary":"","htmlStringContent":"<!-- begin item aa2dc2af-1e84-4400-84c6-a71600da4ee3 --><!-- begin field bb28064c-0135-417e-93a3-a71600da4f31 --><p><strong>Adverse effects of angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li><strong>Renal impairment </strong>— monitor renal function 1–2 weeks after starting an angiotensin-converting enzyme (ACE) inhibitor, after each increase in dose, and regularly throughout treatment.</li><li><strong>Hyperkalaemia </strong>— monitor<strong> </strong>serum electrolytes 1–2 weeks after starting an ACE inhibitor, after each increase in dose, and regularly throughout treatment.</li><li><strong>Cough</strong> <ul><li>Cough occurs in about 15% of people taking an ACE inhibitor and may occur at any time after starting treatment — if the cough is troublesome (for example it prevents the person from sleeping) and other causes have been ruled out, consider switching to an angiotensin-II receptor blocker [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</li></ul></li><li><strong>Angioedema</strong><ul><li>ACE inhibitors can cause a non-allergic drug reaction which can precipitate angioedema — stop ACE inhibitor treatment immediately, and consider starting an alternative drug treatment. If possible avoid angiotensin-II receptor blockers as these can also trigger episodes of angio-oedema. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li><li><strong>Dizziness and headaches </strong><ul><li>Dizziness and headaches occur most commonly in people who are hypovolaemic or hyponatraemic — if hypotension is symptomatic, consider reducing the dose of the ACE inhibitor or stopping it.</li></ul></li><li><strong>Other common adverse effects</strong> include abdominal discomfort, dyspepsia, diarrhoea, nausea and vomiting, rash (in particular maculo-papular rash), myalgia, muscle spasms, dyspnoea, chest pain, and fatigue.</li><li><strong>Hepato-biliary disorders</strong> — stop treatment if marked elevation of hepatic enzymes or jaundice occur. This is a very rare adverse effect. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field bb28064c-0135-417e-93a3-a71600da4f31 --><!-- end item aa2dc2af-1e84-4400-84c6-a71600da4ee3 -->","subChapters":[]},{"id":"b392d52d-a321-5db3-856d-6dca843def5f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f4547730-e0a8-4433-bf21-a77700f0e4dc --><h3>Drug interactions</h3><!-- end field f4547730-e0a8-4433-bf21-a77700f0e4dc -->","summary":"","htmlStringContent":"<!-- begin item fbd1c3bd-f0d5-4b40-936b-a77700f0de3c --><!-- begin field 6db54169-e86a-43dc-aaed-a77700f0e4dc --><p><strong>Drug interactions with angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li><strong>Angiotensin-II receptor blockers and aliskerin</strong> — concomitant use of two drugs affecting the renin-angiotensin system increases the risk of hyperkalaemia, hypotension, and renal impairment.<ul><li>People with diabetic neuropathy are particularly susceptible to developing hyperkalaemia and should not receive combination treatment.</li><li>For people for whom combination therapy is considered essential, specialist supervision with close monitoring of blood pressure, renal function, and electrolytes, is recommended. Monitoring should be carried out when treatment commences, then monthly, and also after any change in dose or intercurrent illness.</li></ul></li><li><strong>Diuretics</strong> — ACE inhibitors can cause a very rapid fall in blood pressure in a person who is volume-depleted.<ul><li>Treatment should be initiated at very low doses.</li><li>If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some cases the diuretic dose may need to be reduced, or the diuretic discontinued at least 24 hours beforehand.</li><li>If high-dose diuretic therapy cannot be stopped, close observation is recommended for at least 2 hours following the first dose of ACE inhibitor, or until the blood pressure has stabilised.</li></ul></li><li><strong>Allopurinol</strong> — possible increased risk of leucopenia and hypersensitivity reactions, especially in people with renal impairment.</li><li><strong>Bee/wasp venom extracts</strong> — risk of severe anaphylaxis.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — increased risk of renal impairment, and hypotensive effect antagonised with concomitant use.</li><li><strong>Antacids</strong> — possible decreased absorption of ACE inhibitors with use of an antacid.</li><li><strong>Amiloride, eplerenone, heparins, ciclosporin, potassium canrenoate, potassium salts, triamterene, trimethoprim </strong>— increased risk of hyperkalaemia. Monitoring of electrolytes and renal function may be advised.</li><li><strong>Digoxin</strong> — concomitant use with captopril can increase plasma concentrations of digoxin. Regular monitoring of plasma digoxin concentration is advised.</li><li><strong>Everolimus</strong> — increased risk of angioedema.</li><li><strong>Alpha-blockers, antipsychotics, anxiolytics, beta-blockers, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, diazoxide, hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxisylyte, moxonidine, nitrates, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Insulin, metformin, and sulfonylureas</strong> — enhanced hypoglycaemic effect.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Ciclosporin</strong> — hyperkalaemia may occur during concomitant use of ACE inhibitors with ciclosporin. Monitoring of serum potassium is recommended. </li><li><strong>Heparin</strong> — hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin. Monitoring of serum potassium is recommended.</li><li><strong>Lithium</strong> — concomitant use can increase plasma levels of lithium. Regular monitoring of serum lithium concentrations is advised.</li><li><strong>Sacubitril</strong> — manufacturer advises to avoid concomitant use of lisinopril with sacubitril/valsartan therapy. Lisinopril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan.</li><li><strong>Sodium Aurothiomalate</strong> — flushing and hypotension reported.</li><li><strong>Spironolactone</strong> — increased risk of severe hyperkalaemia- use lowest possible dose of both drugs and monitor renal function closely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 6db54169-e86a-43dc-aaed-a77700f0e4dc --><!-- end item fbd1c3bd-f0d5-4b40-936b-a77700f0de3c -->","subChapters":[]},{"id":"84716737-f3eb-5411-99c5-9eb046d076b6","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 923b7498-578a-4e49-9180-a71600d7bb49 --><h3>Dose and titration</h3><!-- end field 923b7498-578a-4e49-9180-a71600d7bb49 -->","summary":"","htmlStringContent":"<!-- begin item e982a62d-2c80-4590-be0e-a71600d7bbe6 --><!-- begin field 5d2b1f29-d0cb-4eb4-962e-a71600d7bb49 --><ul><li>Start with a low dose of angiotensin-converting enzyme (ACE) inhibitor and gradually titrate upwards (usually every 2–4 weeks depending on the drug) until the target blood pressure has been achieved, or until the person has reached the maximum advised or tolerated dose of ACE inhibitor.</li><li>Advise the person to take the first dose in the evening. If the drug is well-tolerated, subsequent doses should be taken in the morning.</li><li>Check renal function and serum electrolytes 1–2 weeks after each upward titration. Measure blood pressure 4 weeks after each dose change. For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/angiotensin-converting-enzyme-inhibitors/#monitoring\">Monitoring</a>.</li><li>For people who are taking diuretics:<ul><li>If the person is taking low-dose diuretics (for example, bendroflumethiazide 2.5 mg daily), give a low starting dose of an ACE inhibitor.</li><li>Refer people who are taking high-dose diuretics (equivalent to 80 mg furosemide or more) to secondary care to initiate ACE inhibitor treatment.</li></ul></li><li>Details of low starting doses, usual starting doses, and maintenance and maximum doses of ACE inhibitors are given in Table 1.</li></ul><p><strong>Table 1.</strong> Low starting, usual starting, maintenance, and maximum doses of ACE inhibitors for hypertension.</p><table><tbody><tr><td><strong>ACE inhibitor</strong></td><td><strong>Low starting doses*</strong></td><td><strong>Usual starting dose</strong></td><td><strong>Usual maintenance dose</strong></td><td><strong>Maximum dose</strong></td></tr><tr><td>Captopril</td><td>6.25 mg to 12.5 mg single dose, then 6.25 to 12.5 mg twice a day</td><td>12.5 to 25 mg twice a day</td><td>50 to 75 mg twice a day</td><td>75 mg twice a day</td></tr><tr><td>Enalapril</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>20 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Fosinopril</td><td>10 mg once a day</td><td>10 mg once a day</td><td>10 to 40 mg once a day</td><td>40 mg once a day</td></tr><tr><td>Imidapril</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td></tr><tr><td>Lisinopril</td><td>2.5 mg once a day</td><td>10 mg once a day</td><td>20 mg once a day</td><td>80 mg once a day</td></tr><tr><td>Perindopril arginine</td><td>2.5 mg once a day</td><td>5 mg once a day</td><td>5 to 10 mg once a day</td><td>10 mg once a day</td></tr><tr><td>Quinapril</td><td>2.5 mg once a day</td><td>10 mg once a day</td><td>10 to 20 mg twice daily</td><td>40 mg twice daily</td></tr><tr><td>Ramipril</td><td>1.25 mg once a day</td><td>1.25 to 2.5 mg once a day</td><td>2.5 mg to 10 mg once a day</td><td>10 mg once a day</td></tr><tr><td>Trandolapril</td><td>500 micrograms once a day</td><td>500 micrograms once a day</td><td>1 to 2 mg once a day</td><td>4 mg once a day</td></tr><tr><td colspan=\"5\">* Lower starting doses are required for people who are more prone to the adverse effects of ACE inhibitors (such as elderly, frail, or renally impaired people, or people on low-dose diuretics).</td></tr><tr><td colspan=\"5\"><p><strong>Information from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p></td></tr></tbody></table><!-- end field 5d2b1f29-d0cb-4eb4-962e-a71600d7bb49 --><!-- end item e982a62d-2c80-4590-be0e-a71600d7bbe6 -->","subChapters":[]},{"id":"e77a0b00-7e20-5844-ab27-d8e7c7609fbf","slug":"when-to-refer-for-initiation","fullItemName":"When to refer for initiation","depth":3,"htmlHeader":"<!-- begin field 518724df-b3c1-4c36-bbea-a71600d8c98f --><h3>When should an angiotensin-converting enzyme (ACE) inhibitor be initiated in secondary care?</h3><!-- end field 518724df-b3c1-4c36-bbea-a71600d8c98f -->","summary":"","htmlStringContent":"<!-- begin item d711090a-af1a-4644-aeb2-a71600d8c9e6 --><!-- begin field 5c4e6d5d-bcaa-4ae8-999e-a71600d8c98f --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors</strong> should be initiated under specialist supervision and with careful clinical monitoring in those with severe heart failure or in those:<ul><li>Receiving multiple or high-dose diuretic therapy (for example more than 80 mg of furosemide daily or its equivalent).</li><li>Receiving concomitant angiotensin-II receptor blocker or aliskiren.</li><li>With hypovolaemia.</li><li>With hyponatraemia (plasma sodium level less than 130 mmol/L).</li><li>With hypotension (systolic blood pressure below 90 mmHg).</li><li>With unstable heart failure.</li><li>Receiving high-dose vasodilator therapy.</li><li>With known renovascular disease.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 5c4e6d5d-bcaa-4ae8-999e-a71600d8c98f --><!-- end item d711090a-af1a-4644-aeb2-a71600d8c9e6 -->","subChapters":[]},{"id":"76bd693c-9216-57de-ad37-2a7992a3ef8a","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field cabc2c22-e4fc-408d-ad3c-a71600d990fd --><h3>Monitoring</h3><!-- end field cabc2c22-e4fc-408d-ad3c-a71600d990fd -->","summary":"","htmlStringContent":"<!-- begin item 18ff00f8-76ce-4fe7-8658-a71600d991c4 --><!-- begin field 090bb315-1387-49ea-ad55-a71600d990fd --><ul><li>Measure renal function (serum creatinine and estimated glomerular filtration rate) and serum electrolytes before starting treatment.</li><li>Check renal function and serum electrolytes 1–2 weeks after starting treatment and 1–2 weeks after each dose increase. Thereafter, check renal function and serum electrolytes annually unless clinical judgement or abnormal blood testing parameters indicate a need for more frequent monitoring. </li><li>Check blood pressure 4 weeks after each dose titration.</li><li>For people who are at higher risk of hyperkalaemia or deteriorating renal function (for example those with peripheral vascular disease, diabetes mellitus, or pre-existing renal impairment or older people), consider checking renal function and serum electrolytes sooner (within 1 week).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">Smellie et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">London and South East Medicines Information Service et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 090bb315-1387-49ea-ad55-a71600d990fd --><!-- end item 18ff00f8-76ce-4fe7-8658-a71600d991c4 -->","subChapters":[]},{"id":"c7f6c136-7e06-5771-9453-66260884e102","slug":"managing-abnormal-results","fullItemName":"Managing abnormal results","depth":3,"htmlHeader":"<!-- begin field ff50b009-e5ee-4850-baef-a71a00ce6896 --><h3>Managing abnormal results</h3><!-- end field ff50b009-e5ee-4850-baef-a71a00ce6896 -->","summary":"","htmlStringContent":"<!-- begin item 70d09174-07f5-4947-b773-a71a00ce69ed --><!-- begin field db926e42-048e-4094-8135-a71a00ce6896 --><ul><li>Some increase in serum creatinine and potassium is expected after starting or increasing the dose of an angiotensin-converting enzyme (ACE) inhibitor.</li><li><strong>If the eGFR decreases by less than 25%, or serum creatinine </strong><strong>increases</strong><strong> by less than 30%:</strong><ul><li>Do not modify the ACE inhibitor dose and recheck levels in a further 1–2 weeks.</li></ul></li><li><strong>If eGFR decreases by 25% or more, or serum creatinine </strong><strong>increases</strong><strong> by 30% or more:</strong><ul><li>Investigate other causes of deteriorating renal function, such as volume depletion.</li><li>Stop or reduce the dose of the following drugs (where appropriate) if the person is taking them:<ul><li>Nephrotoxic drugs (such as nonsteroidal anti-inflammatory drugs).</li><li>Vasodilators (such as calcium-channel blockers, nitrates).</li><li>Potassium supplements or potassium-sparing diuretics.</li><li>Diuretics (consider dose reduction if the person is hypovolaemic).</li></ul></li><li>If the decrease in eGFR or the increase in serum creatinine persists despite these measures:<ul><li>Stop the ACE inhibitor therapy, or</li><li>Reduce the dose to a previously tolerated lower dose and recheck levels in 5–7 days (add an alternative antihypertensive medication if required).</li></ul></li></ul></li><li><strong>If serum potassium is 5.0 mmol/L or above:</strong><ul><li>Investigate other causes of hyperkalaemia and treat accordingly.</li><li>Stop or reduce the dose of potassium-sparing diuretics (amiloride, triamterene, spironolactone) or nephrotoxic drugs (such as nonsteroidal anti-inflammatory drugs).</li></ul></li><li><strong>If serum potassium persists between 5.0 and 5.9 mmol/L despite these measures, </strong>reduce the dose of ACE inhibitor to a previously tolerated lower dose and recheck levels in 5–7 days.</li><li><strong>Stop ACE inhibitors if serum potassium persists above 6 mmol/L despite these measures.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2014</a>]</p><!-- end field db926e42-048e-4094-8135-a71a00ce6896 --><!-- end item 70d09174-07f5-4947-b773-a71a00ce69ed -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}